Share Print


Office of the Vice Chancellor for Research at Washington University.  University Research Strategic Alliance (URSA) will provide up to six awards for seed funding for new interdisciplinary collaborative research projects to full-time faculty at Washington University.

Letter of intent deadline:  July 1, 2011
Application deadline:  September 2, 2011


Center for Inherited Disease Research (CIDR) High Throughput Genotyping and Sequencing Resource Access (X01)
(PAR-11-210)  CIDR high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes that contribute to human health and disease. The services provided through CIDR focus primarily on needs that can’t be readily handled by individual investigator laboratories.  Application Receipt/Submission Date(s):   Earliest submission date July 1.  Applications are accepted by continuous receipt.

Investigational Nutritigenic Studies for Cancer Prevention (R21)
(PA-08-221)  Intended funding for research projects that can combine information on individual genetic variations from the Human Genome and International HapMap Projects to stimulate small pilot dietary intervention studies. The overarching goal is to examine whether genetic variants can predict individual response to dietary components that alter cancer processes and modify individual susceptibly to cancer. Application Receipt/Submission Date(s): Next submission date June 16.

Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R21)
(PA-09-167)  The overarching goals of this FOA is to encourage investigators to submit high quality, preliminary research of humans that will advance the science of Complementary and Alternative Medicine (CAM) and provide a solid foundation and justification for future research project (R01) grant applications to definitively determine the efficacy of CAM approaches. Application Receipt/Submission Date(s): Next submission date June 16.  Multiple dates.

Developmental Research in Cancer Prognosis and Prediction (R21)
(PA-09-158) The purpose of this FOA is to develop newly discovered biomarkers from initial correlative observations into assays or test systems suitable for use in clinical trials or other types of confirmatory clinical research studies.
Application Receipt/Submission Date(s): Next submission date June 16.  Multiple dates.

National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI) Biology of Manual Therapies (R01 & R21)
(PA-10-209 & PA-10-210) Seeks applications that propose to investigate the basic science and mechanisms of action underlying the biomechanical, immunological, endocrinological and/or neurophysiological consequences of manual therapies, such as spinal manipulation, mobilization and massage therapy.  Application Receipt/Submission Date(s):  Submission date October 5 (R01) October 16 (R21).